Cure pharmaceutical announces addition of two new clinical development programs targeting anti-seizure and antiviral applications

Oxnard, calif.--(business wire)--cure pharmaceutical holding corp. (“cure” or the “company”) (otc: curr), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. the first is an antiviral clinical development program where the company will look to load a known active pharmaceutical ingredient (api) onto its patented drug delivery
CURR Ratings Summary
CURR Quant Ranking